Tison A, Quéré G, Misery L, et al. - In this retrospective cohort study of 112 patients with preexisting autoimmune diseases (PAD) and cancer, researchers examined safety and efficacy of immune checkpoint inhibitors (ICI). Psoriasis (n=31), rheumatoid arthritis (n=20) and inflammatory bowel disease (n=14) were the most frequent PAD. The patients frequently experienced flare/immune related adverse effects, however, most of these were manageable without ICI discontinuation. They observed poorer outcomes in correlation with the receipt of immunosuppressive therapy at baseline.